Despite a 5.7 percent increase in sales to $1,192 million in the third quarter, Allergan reported a net loss of $670.5 million compared with profits of $239.2 million last year. The overall sales increase was 6.3 percent on a currency-neutral basis. Revenues from eye care pharmaceuticals grew by 6.3 percent ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.